Biocon, Asia’s premier biotechnology company, is reportedly planning to launch psoriasis drug Alzumab in the country in the July-September quarter. The company expects sales of Rs 100 crore from the drug over four years.
The company, early in January, only received marketing authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis. Itolizumab is a first in class therapy with a unique mechanism of action (MOA) and an excellent safety profile as indicated during the 52-week Phase III multi-centric clinical study conducted in India. It is the second Novel Biologic developed by Biocon at Asia’s largest Biotech hub in Bangalore.
Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.
